Thymalfasin (Thymosin alpha 1, CAS 69440-99-9) is a high-purity, pharmaceutical-grade immunomodulator synthesized via precision solid-phase peptide synthesis, fully complying with USP and EP quality standards. Its natural human thymosin-mimetic structure enables it to activate T-lymphocytes, enhance natural killer cell activity, and regulate the balance of pro-inflammatory and anti-inflammatory cytokines. Produced with strict control over peptide integrity (purity ≥99%) and biological activity, each batch undergoes rigorous in vitro and in vivo validation, making it a reliable raw material for biopharmaceutical formulation.
This potent peptide immunomodulator stands out for its dual regulatory effect—strengthening immune function in immunocompromised individuals while moderating excessive immune responses. It is clinically proven to support the treatment of viral infections (such as hepatitis B/C) and assist in post-chemotherapy immune recovery for cancer patients. Unlike synthetic immunostimulants, it exhibits excellent biocompatibility with minimal adverse reactions, supporting long-term therapeutic use. Its stable peptide structure allows formulation into injectable solutions and lyophilized powders, catering to diverse clinical and research needs.
Thymalfasin (Thymosin alpha 1, CAS 69440-99-9) caters to professional users: pharmaceutical manufacturers developing immune-regulating drugs, biotech firms advancing antiviral/oncology therapies, and research institutions studying immune system biology. Its proven clinical efficacy, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing reliability and therapeutic value. Whether for large-scale commercial production or preclinical research, this immunomodulator meets the stringent demands of the global biopharmaceutical industry.
